Can COVID-19 Cause High Cholesterol? The Connection

COVID-19 can raise cholesterol levels, and the effect persists well beyond the acute infection. A large cohort study following hundreds of thousands of people found that survivors had roughly a 25 percent higher risk of developing abnormal cholesterol in the year after infection, including elevated LDL (“bad” cholesterol) and triglycerides, along with drops in protective HDL. The relationship between the virus and lipid metabolism turns out to be more complex than a simple one-way arrow, though, with pre-existing cholesterol problems also influencing how severe the infection becomes.

What the Largest Study Found

The most comprehensive look at this question comes from a study published in The Lancet Diabetes & Endocrinology that tracked COVID-19 survivors from the U.S. Department of Veterans Affairs health system. Compared to people who were never infected, those who survived the first 30 days of COVID-19 had an increased risk of developing total cholesterol above 200 mg/dL, LDL above 130 mg/dL, triglycerides above 150 mg/dL, and low HDL below 40 mg/dL. When all these lipid abnormalities were combined, the overall risk was about 24 percent higher in COVID survivors. The study also found that the need for cholesterol-lowering medications like statins jumped by more than 50 percent in the COVID group, translating to roughly 25 extra people per 1,000 needing lipid-lowering drugs within a year of infection.¹

These weren’t small or borderline effects. The composite risk of any dyslipidemia outcome, whether a lab abnormality or new use of lipid-lowering medications, carried a hazard ratio of 1.31, meaning roughly a 31 percent increase. Per 1,000 people followed for a year, this amounted to about 54 extra cases of dyslipidemia that could be attributed to the infection itself.¹

How the Virus Disrupts Lipid Metabolism

SARS-CoV-2 doesn’t just cause respiratory illness and then leave the metabolic system alone. The virus directly affects the liver, which is where most of your cholesterol is produced and regulated. Research has shown that the spike protein of SARS-CoV-2 triggers metabolic rewiring in liver cells, ramping up glycolytic flux and altering how these cells process glucose and energy substrates.² When liver cells shift their metabolic priorities in response to the virus, the downstream effects on cholesterol production can be significant.

A separate piece of the puzzle involves the inflammatory cascade that COVID-19 sets off. The intense immune response activates pathways involved in cholesterol synthesis, particularly a protein called SREBP-2, which acts as a master switch for cholesterol production. When the body’s inflammatory signaling goes haywire during a cytokine storm, SREBP-2 activation ramps up cholesterol and lipid synthesis in ways that go beyond normal immune defense.³ This creates a feedback loop: inflammation drives cholesterol synthesis upward, and the altered lipid environment may in turn fuel more inflammation.

There’s also a vascular dimension. COVID-19 tends to lower HDL cholesterol, which normally acts as a protective scavenger in the bloodstream. When HDL drops, its ability to neutralize harmful oxidized LDL particles weakens. Oxidized LDL is far more damaging to blood vessel walls than regular LDL, and the loss of HDL’s antioxidant function during and after infection may accelerate the kind of vascular damage that leads to atherosclerosis.⁴ Oxidative stress combined with the inflammatory storm also triggers platelet activation and clotting in small blood vessels, compounding the cardiovascular toll.⁵

The Lipid Rollercoaster During and After Infection

One reason this topic confuses people is that cholesterol doesn’t just go up and stay up in a straight line. During the acute phase of a COVID-19 infection, total cholesterol and LDL levels often drop. This might sound like good news, but it’s actually a sign that the body is diverting cholesterol into the immune response, and the virus itself is hijacking cholesterol-rich structures on cell membranes to gain entry into cells.⁶ So a blood test taken while you’re sick with COVID might actually show lower-than-usual cholesterol.

After recovery, the picture reverses. Research tracking lipid profiles in the post-recovery phase has found a rebound effect: total cholesterol, LDL, and HDL all climb back up, sometimes overshooting pre-infection levels. Triglycerides, which tend to spike during acute illness, may come back down but not always to where they started.⁷ This post-recovery lipid rebound is part of what drives the elevated cholesterol numbers seen months after the infection has resolved. Whether these shifts settle back to normal over a longer period or represent a permanent metabolic shift is still an open question, but the VA cohort data showing persistent effects at 12 months suggests that for many people, the changes linger.

The Other Direction: How Cholesterol Affects COVID Severity

The relationship between COVID-19 and cholesterol runs in both directions. People who already had abnormal lipid profiles before catching the virus tended to fare worse. A study looking at pre-infection lipid panels found that patients who went on to develop severe COVID-19 had lower HDL and higher triglycerides before they ever got sick, while LDL levels were similar regardless of eventual disease severity.⁸ In other words, the specific pattern of lipid dysfunction mattered: low HDL and high triglycerides predicted trouble, while LDL alone was less useful as a marker.

Why would existing cholesterol problems make COVID worse? One mechanism involves the cell membranes themselves. SARS-CoV-2 enters cells through cholesterol-rich regions called lipid rafts on the cell surface, and higher membrane cholesterol generally makes viral entry more efficient.⁶ Beyond the point of viral entry, elevated cholesterol may also increase susceptibility through inflammatory pathways and by promoting the instability of atherosclerotic plaques, which can raise the risk of dangerous cardiovascular events during the infection.⁹ A systematic review of comorbidity data confirmed that diabetes, hypertension, and abnormal cholesterol levels all showed a clear relationship with how severe the disease became.¹⁰

This bidirectional relationship creates a concerning cycle: COVID-19 worsens your lipid profile, and a worsened lipid profile could make a future infection more dangerous. For people who were already managing borderline cholesterol before the pandemic, this is worth understanding clearly.

Children and Adolescents Are Affected Too

Adults weren’t the only ones to see post-COVID lipid changes. A large electronic health records study from the RECOVER Initiative found that children and adolescents who had documented SARS-CoV-2 infection were significantly more likely to develop abnormal lipid levels in the months afterward. The risk of abnormal HDL was about 24 percent higher, abnormal triglycerides about 28 percent higher, and abnormal LDL roughly 19 percent higher compared to children who had not been infected. These same children also had a 15 percent higher risk of developing an abnormal BMI.¹¹

This finding is striking because children generally have much healthier lipid profiles than adults, and pediatricians don’t typically screen for cholesterol problems in young kids. Metabolic research has also shown that even when children had milder respiratory symptoms from COVID-19, the metabolic disturbances in their bodies looked similar to what happens in adults with severe disease, pointing to a shared inflammatory response that doesn’t spare younger patients just because their lungs handle the virus better.¹² Parents who notice weight changes or receive unexpected lab results after their child recovers from COVID-19 should be aware that the virus could be driving metabolic shifts that warrant monitoring.

Genetics May Determine Who Gets Hit Hardest

Not everyone who catches COVID-19 ends up with lipid problems, and genetics plays a role in who is most vulnerable. The APOE gene, which encodes a protein involved in transporting cholesterol in the bloodstream, comes in several variants. People carrying the e4 variant, already known for raising the risk of heart disease and Alzheimer’s, appear to face dramatically higher risks from COVID-19. One study found that carrying the e4 allele increased the risk of severe COVID more than fivefold, and people with two copies of e4 faced a 17-fold increase in the risk of severe disease.¹³

APOE e4 carriers already tend toward higher LDL and are more susceptible to cardiovascular disease under normal circumstances. When COVID-19 pushes the lipid system into disarray, these individuals may experience a more exaggerated and persistent metabolic hit. This is an area where population-level statistics about post-COVID cholesterol changes might understate the risk for certain individuals. If you know you carry an APOE e4 variant from prior genetic testing, the case for close lipid monitoring after a COVID infection is even stronger.

Does COVID Vaccination Affect Cholesterol?

A separate question that comes up frequently is whether the COVID vaccines themselves influence cholesterol. A cross-sectional analysis of data from the 2023 National Health Interview Survey found a statistically significant association between COVID-19 vaccination and higher rates of hypercholesterolemia, with an odds ratio of about 1.54 after adjusting for multiple confounding factors.¹⁴

Before jumping to conclusions, this kind of study has important limitations. Cross-sectional surveys capture a snapshot in time and can’t establish that vaccination caused the cholesterol elevation. People who chose to get vaccinated may differ systematically from those who didn’t in ways that affect cholesterol, including healthcare engagement, medication use, and willingness to get lab work done that reveals a pre-existing condition. The association could also be confounded by the fact that many vaccinated individuals had also been infected with COVID-19 at some point. The finding is worth noting, but it is far from definitive evidence that vaccines raise cholesterol in the way that infection itself does.

What Happens in the Gut Matters Too

An underappreciated part of the story involves the gut. COVID-19 frequently causes gastrointestinal symptoms, and the virus can disrupt the gut microbiome in ways that ripple through metabolic health. One case study documented that targeted nutritional modulation of gut bacteria in a patient with persistent post-COVID symptoms led to improvements in the serum lipid profile. The beneficial changes were linked to recovery of specific bacterial species known to produce short-chain fatty acids, which play a role in regulating cholesterol absorption and metabolism.¹⁵ This is a single case, not a clinical trial, so the evidence is preliminary. But it aligns with what we know about how gut health influences lipid metabolism more broadly, and it suggests that dietary and microbiome-focused interventions could be a piece of managing post-COVID cholesterol changes.

Behavioral and Lifestyle Factors

It would be easy to dismiss post-COVID cholesterol changes as a byproduct of being sedentary during illness and recovery. Prolonged bed rest and inactivity certainly affect metabolic health. However, the evidence suggests this explanation is insufficient. Research on long COVID patients has found that while they tend to be less active than healthy individuals, many maintain physical activity levels comparable to the average American adult. The muscle and metabolic changes seen in long COVID are also distinct from those caused by strict bed rest, which typically involves muscle wasting and insulin resistance.¹⁶ This means deconditioning alone doesn’t account for the lipid disruption. Something about the infection itself is doing the metabolic damage.

That said, lifestyle factors clearly matter for recovery. People who were already eating poorly, carrying extra weight, or living sedentary lives before infection probably experience the post-COVID lipid hit on top of an already unfavorable baseline. For these individuals, the metabolic fallout from infection may push them across clinical thresholds that trigger a statin prescription, whereas someone starting from a healthier baseline might see changes that stay within normal range despite the same degree of viral disruption.

Statins as a Potential Treatment for Long COVID

Given the overlap between COVID-19’s effects and cardiovascular risk, researchers are actively investigating whether statins could help with post-COVID recovery beyond just lowering cholesterol numbers. The STRONGER trial, a randomized clinical trial, is testing whether 12 months of atorvastatin improves cognitive processing speed and reduces brain inflammation in people with persistent neurological symptoms after COVID-19.¹⁷ The trial is using brain imaging alongside cognitive testing to determine whether the anti-inflammatory and vascular-protective properties of statins extend to repairing post-COVID neurological damage. Results are not yet available, but the fact that the study exists speaks to how seriously researchers are taking the metabolic and vascular consequences of the infection.

Statins have well-known anti-inflammatory effects beyond their cholesterol-lowering action, including stabilizing the lining of blood vessels and reducing oxidative stress. If the post-COVID lipid changes are partly driven by persistent vascular inflammation, statins could theoretically address both the cholesterol numbers and some of the underlying damage causing long COVID symptoms. Whether this pans out in practice is an open question that trials like STRONGER are designed to answer.

When to Check Your Cholesterol After COVID

If you’ve had COVID-19 and haven’t had bloodwork done since, a lipid panel is reasonable to request from your doctor, particularly if your infection was moderate to severe or if you had pre-existing metabolic risk factors. The VA cohort data showed that the excess risk of dyslipidemia was evident within the first year after infection, so waiting longer than that to check is probably too long for anyone who had significant illness. Even people with mild cases showed some elevated risk, though the effect was more pronounced in those who were hospitalized or needed intensive care.

For children, the situation is trickier. Routine lipid screening in kids isn’t standard practice outside of specific risk factors, and most pediatricians wouldn’t think to order it after a COVID infection. But the RECOVER data showing a roughly 23 percent higher composite risk of abnormal lipids in post-COVID children suggests that screening could catch early metabolic changes, especially in children who also experienced weight gain during or after their illness.¹¹ This doesn’t mean every child who had a sniffle needs a blood draw, but for kids who had confirmed infections and are showing signs of metabolic change, a conversation with the pediatrician is warranted.

1
The Lancet Diabetes & Endocrinology. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study
2
Nature Communications Biology. The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes
3
PubMed Central. Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19
4
PubMed Central. Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis
5
PubMed Central. Oxidative stress indexes as biomarkers of the severity in COVID-19 patients
6
Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications
7
Scientific Reports. Metabolic implications of COVID-19 with a focus on lipid profiles and inflammatory markers
8
Scientific Reports. Low HDL and high triglycerides predict COVID-19 severity
9
PubMed Central. Possible mechanisms of cholesterol elevation aggravating COVID-19
10
PubMed Central. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review
11
PubMed Central. Post-acute dyslipidemia and abnormal BMI in children and adolescents with COVID-19: An EHR Cohort Study from the RECOVER Initiative
12
PubMed Central. Children with Post COVID-19 Multisystem Inflammatory Syndrome Display Unique Pathophysiological Metabolic Phenotypes
13
Scientific Reports. The association of APOE genotype with COVID-19 disease severity
14
PubMed Central. Association between coronavirus disease 2019 vaccination and hypercholesterolemia: A cross-sectional study from the 2023 National Health Interview Survey
15
mBio. Nutritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome
16
Trends in Endocrinology & Metabolism. Skeletal muscle adaptations in long COVID
17
PubMed Central. STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER): study protocol for a randomised, open label clinical trial